Equities Analysts Issue Forecasts for Palatin Technologies, Inc.’s Q1 2025 Earnings (NYSEAMERICAN:PTN)

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Palatin Technologies in a report issued on Tuesday, October 1st. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($0.51) per share for the quarter. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. HC Wainwright also issued estimates for Palatin Technologies’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($2.03) EPS.

Palatin Technologies Price Performance

Shares of Palatin Technologies stock opened at $0.83 on Thursday. Palatin Technologies has a 1 year low of $0.68 and a 1 year high of $5.65. The firm has a market cap of $16.01 million, a P/E ratio of -0.33 and a beta of 1.01.

Palatin Technologies (NYSEAMERICAN:PTN) last posted its quarterly earnings results on Monday, September 30th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter. The business had revenue of $0.35 million for the quarter.

Institutional Trading of Palatin Technologies

A hedge fund recently bought a new stake in Palatin Technologies stock. Armistice Capital LLC bought a new stake in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,678,101 shares of the biopharmaceutical company’s stock, valued at approximately $3,272,000. Armistice Capital LLC owned 8.66% of Palatin Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 11.50% of the company’s stock.

Palatin Technologies Company Profile

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.